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ABSTRACT
Background: The beneficial cardiovascular effects of vegetables
may be underpinned by their high inorganic nitrate content.
Objective: We sought to examine the effects of a 6-wk once-daily
intake of dietary nitrate (nitrate-rich beetroot juice) compared with
placebo intake (nitrate-depleted beetroot juice) on vascular and
platelet function in untreated hypercholesterolemics.
Design: A total of 69 subjects were recruited in this randomized,
double-blind, placebo-controlled parallel study. The primary end-
point was the change in vascular function determined with the use
of ultrasound flow-mediated dilatation (FMD).
Results: Baseline characteristics were similar between the groups,
with primary outcome data available for 67 patients. Dietary nitrate
resulted in an absolute increase in the FMD response of 1.1% (an
w24% improvement from baseline) with a worsening of 0.3% in
the placebo group (P , 0.001). A small improvement in the aortic
pulse wave velocity (i.e., a decrease of 0.22 m/s; 95% CI: 20.4,
20.3 m/s) was evident in the nitrate group, showing a trend (P =
0.06) to improvement in comparison with the placebo group.
Dietary nitrate also caused a small but significant reduction
(7.6%) in platelet-monocyte aggregates compared with an in-
crease of 10.1% in the placebo group (P = 0.004), with statisti-
cally significant reductions in stimulated (ex vivo) P-selectin
expression compared with the placebo group (P , 0.05) but
no significant changes in unstimulated expression. No adverse
effects of dietary nitrate were detected. The composition of the
salivary microbiome was altered after the nitrate treatment but
not after the placebo treatment (P , 0.01). The proportions of 78
bacterial taxa were different after the nitrate treatment; of those
taxa present, 2 taxa were responsible for .1% of this change,
with the proportions of Rothia mucilaginosa trending to increase
and Neisseria flavescens (P , 0.01) increased after nitrate treat-
ment relative to after placebo treatment.
Conclusions: Sustained dietary nitrate ingestion improves vascular
function in hypercholesterolemic patients. These changes are asso-
ciated with alterations in the oral microbiome and, in particular,
nitrate-reducing genera. Our findings provide additional support
for the assessment of the potential of dietary nitrate as a preventative
strategy against atherogenesis in larger cohorts. This trial was reg-
istered at clinicaltrials.gov as NCT01493752. Am J Clin Nutr
2016;103:25–38.
Keywords: endothelium, microbiome, nitric oxide, vascular,
vegetable
INTRODUCTION
Currently, there is a relative paucity in broadly acceptable
effective primary prevention options for cardiovascular disease
(CVD)9 (1, 2). In this regard, a focus on identifying strategies
that target major but modifiable risk factors, particularly the diet,
that might also operate as preventative strategies to avoid
pharmacotherapeutics is clearly of value.
Vascular dysfunction is thought to play a major role in the
progression of CVD, particularly in atherosclerosis (3). This
change occurs at the very earliest stages of CVD development,
preceding any evidence of disease (4), and is associated with most
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risk factors including hypercholesterolemia (5, 6). Indeed, mea-
sures of vascular function, particularly brachial artery flow-
mediated dilatation (FMD) and aortic pulse wave velocity
(aPWV), have been proposed to inform not only on the extent of
atherosclerotic disease (4, 7, 8) but also of future risk (9, 10).
Mechanistically, vascular dysfunction is characterized by a re-
duced bioavailability of the endothelium-derived vasoprotective
molecule NO. NO is a vasodilator with associated antiplatelet, anti-
inflammatory, and antiproliferative effects that underlie its critical
role in sustaining cardiovascular health (11). The dysfunction of
the conventional L-arginine/NO–synthase pathway and enhanced
scavenging of NO underlie the reduced bioavailability in in-
dividuals at risk of CVD including those with hypercholesterol-
emia (12), which is a phenomenon reflected by impaired FMD
responses. Thus, approaches that might restore this lost NO have
obvious therapeutic potential.
A dietary approach to provide the sustained restoration of nitric
oxide concentrations on the basis of the delivery of inorganic
nitrate has been identified. Inorganic nitrate is converted to nitrite
by nitrate-reductase expressing bacteria, which naturally reside in
the oral cavity. Once salivary nitrite is swallowed, some of it enters
the systemic circulation, where it undergoes a subsequent chemical
reduction to NO, which is a reaction that is facilitated by mam-
malian nitrite reductases (13). Previous evidence has shown that,
although a single, acute dietary nitrate load acutely improves
aPWV, it has no effect on endothelial function per se in healthy
volunteers (14). However, a single dose of inorganic nitrate pro-
tects against a transient vascular dysfunction that is expressed as
a decreased FMD, induced experimentally by an ischemia and
reperfusion insult (15), as well as decreasing platelet sensitivity to
activating stimuli (16). In addition, more recently in a study in
which blood pressure (BP) was the primary outcome measure,
sustained dietary nitrate ingestion in addition to lowering BP also
improved vascular function in hypertensive patients, reflected by
increased FMD responses (17). Thus, in a prospective trial, we
sought to determine whether dietary nitrate as a method of NO
delivery might provide an improvement in vascular function in
a cohort of otherwise healthy hypercholesterolemics after a once-
daily 6-wk dietary nitrate intervention in the form of nitrate-rich
beetroot juice. In addition, we also assessed the possible effect on
platelet function as a secondary outcome measure.
METHODS
Study design and subjects
This randomized, double-blind, placebo-controlled parallel
trial was approved by the National Research Ethics Service
Committee London-Stanmore (study 11/LO/0715) and complied
with the Declaration of Helsinki. The trial was registered at
clinicaltrials.gov as NCT01493752.
Subjects were recruited between September 2011 and May
2013 from advertisements within primary care facilities and from
a dedicated cholesterol clinic within The Royal London Hospital.
Sixty-nine nonsmoking, nondiabetic, otherwise healthy hyper-
cholesterolemic men and women aged 18–80 y with BMI (in
kg/m2) from 18.5 to 40 were recruited. Inclusion criteria in-
cluded a total serum cholesterol concentration .6.0 mmol/L or any
elevation of LDL cholesterol or triglycerides with a QRISK 2
(cardiovascular disease risk calculator; National Health Service)
score.15%. All participants were expected to be free from any use
of statins or other cholesterol-lowering medication for$2 mo before
screening. All participants provided written informed consent before
their inclusion in the study.
After successful screening, participants were randomly assigned
1:1 to receive daily either 250 mL naturally nitrate-rich beetroot
juice or placebo nitrate-depleted beetroot juice (James Whites
Drinks). The placebo juice was generated from the same batch of
nitrate-replete juice by using a standard anion exchange resin as
described previously (18). Visually, there was no detectable dif-
ference between the juices. Previous spectral, ion-concentration,
sugar, and ascorbate content analysis and taste testing has confirmed
no differences in color and constituents between the two types of
juice (18, 19). All study personnel were blind to the treatment al-
location until the study had been completed and all analyses were
performed. The random assignment was generated via an online
randomization program, and the packing of juice was undertaken by
an individual who was not involved in patient contact or the sample
collection and analysis. The code for the random assignment was
only revealed once all data had been collected and computed. The
random assignment was conducted in 2 blocks to enable a balance
between the groups at the midpoint of recruitment.
Participants were invited to attend their first study visit#2 wk of
screening and were expected to withhold medications on the
morning of study visits with any last medications consumed $12 h
before study visits in the case of antihypertensives and 24 h before
study visits in the case of aspirin. Participants were expected to fast
12 h before study visits having consumed a low-nitrate diet and
having refrained from any strenuous exercise 24 h before study
visits. Of 69 recruited subjects, 2 individuals withdrew consent at the
time of the first visit (Figure 1). A single patient was taking 75 mg
aspirin/d, and 14 patients were hypertensive and taking medications.
During each study visit, the FMD of the brachial artery, a pulse
wave analysis, aPWV (with the use of the noninvasive Vicorder
device; Skidmore Medical Ltd.), and a clinic BP measurement
using a portable BP device (Omron) were performed followed by
a blood collection. A finger-probe pulse oximeter (SpMet;
Massimo Signal Extraction Technology) was used to measure
methemoglobin concentrations in all participants during each
study visit. Blood, urine, and saliva were collected for bio-
chemical assessments. At the end of these measurements, par-
ticipants consumed their first dose of juice. A subgroup of the first
34 enrolled patients also consented to a repeat of all vascular and
BP measurements 3 h after juice ingestion. Participants con-
sumed the juice once daily for the next 6 wk and returned for their
final study visit at 66 1 wk of study visit 1 and were expected to
adhere to all of the same previsit rules.
Primary endpoint
The primary outcome measure in this study was the absolute
percentage change in the FMD response at 6 wk from baseline.
FMD responses were measured at baseline and at 6 wk in both
groups, and the absolute change in the response was calculated
and compared between groups.
Secondary endpoint measures
The principal secondary outcome measures included a within-
group comparison of the FMD response at baseline and at 6 wk
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and assessment of the change at 6 wk from baseline of platelet
reactivity. In addition, we explored other measures of vascular
function including aPWV and pulse wave analysis and also
assessed changes in nitric oxide metabolite concentrations.
Exploratory endpoint measures
A number of additional prespecified exploratory measures
were conducted including measurements of circulating inflam-
matory markers and markers of oxidative stress. These analyses
were undertaken to gain some insight into potential mechanisms
involved in any effects seen and were hypothesis generating only.
In addition, a post hoc exploratory measure of oral-bacterial
community profiling was conducted.
FMD of the brachial artery
Ultrasonography was used to assess the FMD of the brachial
artery and was performed by an experienced operator according
to published protocols (20, 21) and as we have conducted pre-
viously (17).
aPWV and aortic pulse wave analysis measurements
All arterial stiffness measurements were performed with the
patient rested for 10 min in a supine position and awake. Six
participants declined the measurement because of an inability to
tolerate the carotid neck-cuff inflation. The pulse wave from the
carotid and femoral arteries were simultaneously recorded with
the use of an oscillometric method within the Vicorder device
(22) and as described previously (23). The Vicorder software
(Skidmore Medical Ltd.) was used to conduct an aortic transfer
function to calculate the waveform and values for central BP as
previously described (24).
Urine and saliva sampling
Midstream urine samples were collected into sterile pots and
aliquots were stored at2808C pending the analysis of nitrite and
nitrate concentrations with the use of ozone chemiluminescence.
Unstimulated saliva was collected and centrifuged (14000 3 g,
48C, 10 min), and the supernatant fluid was stored at 2808C
pending an analysis by ozone chemiluminescence.
Oral microbiome profiling
Oral microbiome community profiling was conducted on
samples collected at baseline and after 6 wk of treatment from 16
patients in the nitrate group and 14 patients in the placebo group
(i.e., 32 and 28 samples, which made a total of 60 samples). DNA
was extracted from the pellets for each saliva sample with the use
of the GenElute Bacterial DNA Extraction Kit (Sigma-Aldrich).
Extractions were conducted according to the manufacturer’s in-
structions with an additional lysis step to increase the recovery
of Gram-positive bacterial DNA. Samples were incubated with
a 45-mg/mL lysozyme solution at 378C for 30 min. Samples
were subjected to 16S ribosomal RNA gene polymerase chain
reaction (PCR) and 454 pyrosequencing as previously described
FIGURE 1 CONSORT flowchart of study. CONSORT, Consolidated Standards of Reporting Trials.
INORGANIC NITRATE AND HYPERCHOLESTEROLEMIA 27
(25). An w500-bp region of the 16S ribosomal RNA gene
(covering V1–V3) was PCR amplified from extracted DNA
samples with the use of composite fusion primers comprising uni-
versal 16S primers (27FYM and 519R) along with GS-FLX Titanium
Series adapter sequences (A & B, Roche) for 454 pyrosequencing
with the use of the Lib-L emPCR (Roche) method. Previously de-
scribed unique 12 base error-correcting Golay barcode sequences
were incorporated into the forward primers (5#-CCATCTCATCCC-
TGCGTGTCTCCGACTCAG-NNNNN NNNNNNN-AGAGTTT-
GATYMTGGCTCAG-3#) to enable the pooling of samples in the
same sequencing run. The appropriate barcoded A-27FYM and
the B-519R (5#-CCTATCCCCTGTGTGCCTTGGCAGTCTCAG-
GWATT ACCGCGGCKGCTG-3#) primers were used in PCRs
with Extensor Hi-Fidelity PCR Mastermix (Thermo Scientific)
(25).
Blood sampling
Blood was collected into evacuated tubes (BD Bioscience) that
contained EDTA (for chemiluminesence), 3.2% buffered sodium
citrate (for aggregation assay and platelet flow cytometry), or
a clot activator and gel (for serum cholesterol) through a 21-
gauge butterfly needle inserted into an antecubital vein. For the
measurement of nitrite and nitrate concentrations, blood samples
were centrifuged immediately (1300 3 g, 48C, 10 min), and the
supernatant fluid was collected and stored at 2808C pending an
analysis with the use of ozone chemiluminescence. Serum
cholesterol samples were sent to the St. Bartholomew’s Hospital
biochemistry laboratory for analysis, and uric acid was mea-
sured with the use of a colorimetric kit according to the man-
ufacturer’s instructions (Sigma-Aldrich). For plasma cyclic
guanosine-5’-monophosphate (cGMP) determination, blood was
collected into tubes containing the phosphodiesterase inhibitor,
3-isobutyl-1-methylxanthine (100 mmol/L; Sigma-Aldrich), and
plasma cGMP concentration was measured with the use of an
enzyme immunoassay kit in accordance with the manufacturer’s
instructions (GE Healthcare). A number of other markers of
oxidative stress and inflammation, i.e., plasma [CXCL1], high-
sensitivity C-reactive protein (hs-CRP), and oxidized LDL, were
measured with the use of specialized kits according to the
manufacturers’ instructions.
Measurement of nitric oxide–related species
Briefly, ozone chemiluminescence was used to determine total
nitrate and nitrite (NOx) concentrations, and samples were added
to 0.1 mmol/L vanadium (III) chloride in 1 mmol/L hydro-
chloric acid refluxing at 958C under nitrogen. Nitrite concen-
trations were determined by the addition of samples to 0.09
mmol/L potassium iodide in glacial acetic acid under nitrogen at
room temperature. [Nitrate] was calculated by the subtraction of
[nitrite] from [NOx] as previously described (26).
Apparent total N-nitroso compounds (NOCs) were measured
in urine with the use of a modification of methods that were
previously validated (27, 28) with an Ecomedics CLD 88 Ex-
halyzer (Ecomedics). Urine samples were separated into three
500-mL tubes. A total of 100 mL urine was mixed with 500 mL
of a 5% (weight:volume) sulfanilamide solution to remove ni-
trite and injected into a purge vessel that was kept at 608C and
filled with a standard tri-iodide reagent (38 mg I2 was added to
a solution of 108 mg KI in 1 mL H2O; to this mixture, 13.5 mL
glacial acetic acid was added) to determine total NOCs. To de-
termine ferricyanide stable compounds (nitrosyl iron) to a sample
of 100 mL a 10 mmol/L aqueous solution of K3Fe(CN)6 was
added before analysis. Total nitrosyl iron compounds were de-
termined as the difference between apparent total nitroso com-
pounds with and without the addition of K3Fe(CN)6.
Platelet flow cytometry
Whole blood flow cytometry was used to measure platelet
P-selectin with the use of a modification of previously published
protocols and recommendations (16, 29, 30). The platelet pop-
ulation was identified via labeling with a CD42b (1:25; eBio-
science) monoclonal antibody conjugated to allophycocyanin and
a CD62P (P-selectin; eBioscience) monoclonal antibody conju-
gated to fluorescein isothiocyanate, which was used to determine
the P-selectin expression. Isotype controls for CD62P and CD42b
were used to ensure antibody specificity. All samples were run in
duplicate. Samples were incubated at room temperature for
20 min with phosphate-buffered saline, ADP (10 mmol/L;
Labmedics), collagen (3 mg/mL; Takeda), or adrenaline
(10 mmol/L; Labmedics) before fixing with 1% paraformaldehyde
(Sigma-Aldrich) and analyzed with the use of a Becton Dickinson
FACSCalibur flow cytometer (Becton Dickinson). A total of
10,000 platelets were acquired in the CD42b-positive region.
Results were expressed as the percentage of platelets positive for
P-selectin (16).
Platelet-monocyte aggregate expression
Platelet-monocyte aggregates (PMAs) were determined with
the use of a modification of previously published protocols (30)
with antibodies that were selective for platelet CD42b, and
monocyte-marker CD14 (BD Bioscience) samples were analyzed
TABLE 1
Baseline characteristics1
Variable
Group
Nitrate (n = 33) Placebo (n = 34)
Age, y 53.3 6 10.12 53.2 6 11.8
Sex, M:F, n 12:21 12:22
BMI, kg/m2 26.8 6 4.9 26.7 6 5.1
Baseline SBP, mm Hg 125.2 6 15.1 122.7 6 15.2
Baseline DBP, mm Hg 76.3 6 8.6 78.1 6 11.2
Total cholesterol, mmol/L 6.7 (6.0–7.3)3 6.7 (6.3–7.5)
LDL, mmol/L 4.3 (3.7–5.1) 4.4 (3.9–5.1)
Treated hypertensives, n 9 5
Medications, n
ACE inhibitor/ARB 3 4
Calcium antagonists 4 4
b-Blocker 1 0
Thiazide diuretic 5 1
1ACE, angiotensin-converting enzyme; ARB, angiotensin receptor
blocker; DBP, diastolic blood pressure; SBP, systolic blood pressure.
2Mean 6 SD (all such values for normally distributed variables).
3Median; IQR in parentheses (all such values for non–normally distrib-
uted variables).
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with the use of a Becton Dickinson Fortessa flow cytometer
(Becton Dickinson). Isotype controls were conducted.
Measurements of plasma oxidized LDL concentration, uric
acid, CXCL1, and hs-CRP concentration
A sandwich ELISA (Mercodia) that was based on the
monoclonal antibody mAB-4E6 as described previously (31) was
used to measure plasma oxidized LDL concentrations. CXCL1
concentrations in plasma samples were determined with the use
of a human CXCL1/GROa DuoSet ELISA Development kit
according to the manufacturer’s guidelines (R&D Systems).
Plasma hs-CRP concentrations were measured with the use of a
CRP ELISA kit in accordance with the manufacture’s guidelines
(eBioscience). The concentration of hs-CRP is a predictor of a
cardiovascular event, and patients can be stratified into low-risk
(,1.0 mg/L), moderate-risk (1.0–3.0 mg/L), and high-risk (.3.0
mg/L) groups (32). Data obtained from the measurement of hs-
CRP was classified accordingly for analysis. Uric acid concentra-
tions were determined with the use of a commercially available kit
(Sigma-Aldrich) and per the manufacturer’s guidelines.
Statistical analysis
The study was powered for the primary outcome measure
of the percentage change in the FMD response at 6 wk from
baseline. With the assumption of an average 6 SD improvement
of FMD of 1.1 6 1.45% and the assumption of no change in the
placebo group, 30 volunteers were required within each group
for a statistical power of 0.8 at a significance level of a = 0.05.
Thus, a total of 60 patients were required. We assumed a po-
tential 10% dropout rate (as per our in-house experience), which
FIGURE 2 Dietary nitrate elevates plasma, salivary, and urinary nitrite and nitrate concentrations in hypercholesterolemic patients. Mean6 SD effects of
6 wk of dietary nitrate consumption (250 mL nitrate-rich juice/d) or placebo consumption (250 mL nitrate-depleted juice/d) on nitrite and nitrate concen-
trations in plasma (A and B), saliva (C and D) and urine (E and F), respectively. n = 33 in the nitrate group; n = 32 in the placebo group. ****Significant, P ,
0.001 (1-factor ANOVA with Bonferroni posttests). There were no significant differences in any comparisons between baseline measures in the nitrate and
placebo groups.
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resulted in a total recruitment target of 66 patients. These cal-
culations were based on a number of previous published ob-
servations. Improvements in FMD were noted after 6 wk of
artichoke juice intake (33) and also by 2 additional studies with
walnuts (34) and one recent meta-analysis (35) that assessed the
effects of chronic polyphenol dietary interventions. The aver-
aged improvement across all of these studies was an absolute
increase of 1.1% (with an average absolute FMD response of
5%), which approximated to an improvement of 25%. These
proposed numbers also provided sufficient power for the out-
come measure of improved FMD for within-group comparisons.
With the use of the conservative estimates of an expected in-
crease in FMD of 25% from 5% to 6.7% after 6 wk of beetroot
juice intake in this population, a sample size of 20 was needed to
detect a difference with a power of 0.8 at significance level of
a = 0.05 [assuming an SD of ultrasound FMD of 2.5 (21)] for
a within-group comparison with baseline.
Baseline demographic and clinical variables were summarized
for each group of the study. Statistical comparisons for the pri-
mary outcome measure were between the dietary nitrate-treated
and placebo-treated group. An unpaired t test was used for the
comparison of the change in the FMD response between groups.
For within-group comparison, a paired t test was used. All
P values were 2 tailed.
For the platelet measures, ANOVA with Bonferroni posttests
were applied to compare the baseline with the 6 wk time point for
the within-group comparison. For data with skewed distribution
data (platelet P-selectin expression), the Kruskal-Wallis test was
used with Dunn’s post-tests for within-group comparisons. All
data were analyzed with the use of Prism software version 5
(Graphpad). All exploratory data are expressed as per Consoli-
dated Standards of Reporting Trials guidelines with data showing
a normal distribution as means 6 SDs, data with a skewed dis-
tribution as medians and IQRs, and effect sizes (i.e., differences
from baseline) shown as means with 95% CIs.
For the bacterial community analysis, the data were analyzed
with the use of the mothur pipeline. Sequences were filtered to
exclude sequences that were shorter than 440 bases. Operational
taxonomic units (OTUs) were built at a distance cutoff of 0.15
and identified with the use of the mothur Bayesian classifier with
reference to the Human Oral Microbiome Database reference
dataset (36). The thetaYC metric (37) was used to generate dis-
tance matrices from the sequence libraries, which were visualized
as principal coordinates analysis plots. Three-dimensional prin-
cipal coordinates analysis plots were generated in the R program
(r-project.org) with the use of the rgl package. Treatment groups
were compared bymeans of an analysis ofmolecular variance (38),
which currently stands as the most-appropriate methodology of
choice for the assessment of change in a microbial community
analysis (39), and OTUs that were differentially associated with
treatment groups were determined by means of the Metastats
program (40) and visualized by means of LefSe (41).
RESULTS
In this study, 67 participants completed both study visits. Two
participants withdrew consent after screening at the time of visit
1. One participant wished to unblind the intervention before
continuing, and the other participant felt unwell at the time of the
first visit. The primary outcome measure of FMD was conducted TA
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in all participants; however, full data sets for the analysis were
generated for only 65 participants (32 volunteers who received
the placebo and 33 volunteers who received dietary nitrate),
which was attributed to a loss of brachial artery measurements as
a consequence of inadequate electrocardiographic gating for one
participant and because of a file corruption for another participant
(Figure 1).
The nitrate content of the active treatment juice was 24.26 7.7
mmol/L, which gavew6.0 mmol nitrate in a 250-mL daily dose,
with the placebo juice at 0.053 6 0.12 mmol/L, which gave
w0.001 mmol nitrate/d. Nitrite was below the limits of detection
in both interventions (i.e., ,50 nmol/L). The interventions were
well tolerated and without adverse effects apart from beeturia that
was noted in both groups.
There were no differences in baseline demographics between
the 2 groups of the whole cohort (Table 1) or the subgroup
(Supplemental Table 1). Methemoglobin concentrations were
unaltered by either treatment (Supplemental Table 2). Total
apparent NOCs were similar at baseline with an w40-fold in-
crease in the nitrate group. The treatment of samples to remove all
iron-nitrosyl resulted in a complete loss of signal, which sug-
gested a predominance of iron-nitrosyl (Supplemental Table 1).
Baseline lipid concentrations were similar between the groups
(Table 1, Supplemental Table 1) and unaltered by either in-
tervention (Supplemental Table 2).
Enterosalivary circuit is intact in hypercholesterolemia
There were no differences in baseline plasma cGMP con-
centrations [nitrate group (15.47 6 2.91 nmol/L) compared with
placebo group (15.28 6 3.92 nmol/L), P = 0.82] or NOx con-
centrations between groups (Figure 2). After both 3 h and 6 wk
of dietary nitrate plasma, salivary and urinary [nitrate] and [ni-
trite] were elevated (Figure 2, Supplemental Table 3) with no
changes in other serum electrolytes (baseline and 6-wk data;
Supplemental Table 1).
Inorganic nitrate improves vascular function
There was no difference in the baseline brachial artery di-
ameter or time taken for the peak FMD response between groups
at either the 6-wk (Table 2) or 3-h time point (Table 3). The CV
for the baseline diameter measurement was 2.4 6 1.6% .
There was a significant improvement in the primary outcome
measure of the change in FMD at 6 wk of intervention with
a w24% increase in the nitrate-treated group and a trend for
a small decrease from baseline (w6%) in the placebo group (P =
0.07) with the %change in FMD in the nitrate group significantly
different from the percentage of change in the placebo group
(P , 0.0001) (Table 2, Figure 3). These results were accom-
panied by an improved augmentation index compared with at
baseline and in the placebo group (Table 2) and an improved
aPWV compared with in the placebo group (P = 0.013) with
a trend for significance comparison with the placebo group (P =
0.063). A similar profile of effects on all vascular variables was
also evident at 3 h after the first dose of dietary nitrate (Table 3).
The CV for the %FMD response was 14.3 6 10.3%.
Although small decreases in systolic BP and diastolic BP but
not heart rate (Tables 2 and 3) were evident, differences from
baseline were not significantly different between groups, and post TA
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hoc analyses indicated no correlation between changes in vas-
cular function and systolic BP but a direct correlation with the
change in plasma [nitrite] (Figure 4).
Inorganic nitrate treatment reduces PMA levels and
P-selectin expression
After 6 wk of dietary nitrate intake, PMA levels were reduced
compared with after placebo intake (P = 0.02) (Figure 5) with
a trend for a reduction in platelet P-selectin concentrations
(Supplemental Figure 1) and reduced P-selectin expression in
response to ADP and adrenaline but not to collagen (Supple-
mental Figure 1).
Bacterial community profiling
Changes in [NOx] at 6 wk were associated with alterations in
the oral microbial community (Figure 6) with a significant shift
in the structure of the bacterial community after dietary nitrate
intake that was not evident in the placebo group. The pro-
portions of 78 OTUs were significantly altered in the dietary
nitrate group, and the identity of the OTUs that made up.1% of
the community and the proportions of which increased after
treatment were Neisseria flavescens and Rothia mucilaginosa
(Figure 6). The proportions of N. flavescens were elevated sig-
nificantly after nitrate intake compared with after placebo intake
(P , 0.01); however, the differences did not reach significance
for R. mucilaginosa.
Measurements of plasma uric acid, oxidative stress, and
inflammatory markers
Plasma [uric acid] and the inflammatory marker [CXCL1]
displayed a trend for attenuation after dietary nitrate (Supple-
mental Table 3). Oxidized LDL concentrations were similar at
baseline with a trend for a greater reduction at 6 wk after dietary
FIGURE 3 Dietary nitrate improves vascular function in hypercholesterolemic patients. Mean 6 SD effects of 6 wk of dietary nitrate consumption
(250 mL nitrate-rich juice/d) or placebo consumption (250 mL nitrate-depleted juice/d) on FMD. n = 33 in the nitrate group; n = 32 in the placebo group.
Baseline and 6-wk data are shown for groups before and after intake of nitrate-rich juice and nitrate-depleted placebo juice. P values shown are for within-
group comparisons with the use of paired t test for the comparison of the baseline FMD with the response after 6 wk of intervention. Comparison between
groups are shown with P values for the change from baseline with the use of an unpaired t test. FMD, flow-mediated dilatation.
FIGURE 4 Associations between plasma nitrite concentrations and vascular function measures. Changes were determined from baseline to the 6-wk
time point in FMD relative to changes in plasma nitrite concentration (A) and changes in blood pressure (SBP) (B). (C) Changes in vascular stiffness
aortic PWV are plotted against changes in SBP. Associations were determined with the use of a Pearson’s correlation coefficient assessment. The data
show values for n = 33 in the nitrate group and n = 32 in the placebo group for each correlation analysis. FMD, flow-mediated dilatation; SBP, systolic
blood pressure. PWV, pulse wave velocity.
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nitrate intake, although reductions were evident in both groups
(Supplemental Table 4). Overall, no difference in hs-CRP
concentrations was evident (Supplemental Table 3); however,
stratification at baseline according to low, intermediate, and high
hs-CRP indicated a trend for suppression with nitrate in subjects
with intermediate to high concentrations (Supplemental Table
4). No significant differences were shown for comparisons be-
tween groups of the change from baseline of each of the markers.
The assay variability for CXCL1, oxidized LDL, hs-CRP, and
uric acid was 1.7 6 1.5%, 3.8 6 3.2%, 4.8 6 4.9%, and 3.8 6
4.1%, respectively.
DISCUSSION
In this 6-wk trial of daily inorganic nitrate (beetroot juice)
ingestion compared with intake of a low-nitrate placebo in pa-
tients with hypercholesterolemia, a rise in circulating nitrite was
associated with a w24% improvement in the primary outcome
measure of the FMD response together with improvements in
measures of arterial stiffness. These improvements compared
with aw6% decline in the FMD response in the placebo cohort.
This effect was also associated with reductions in circulating
PMA numbers and reduced platelet P-selectin expression. To-
gether, these data intimate that dietary nitrate might be useful in
improving vascular and platelet functions in hypercholesterol-
emic patients.
Dietary nitrate treatment elevated circulating concentrations of
both nitrate (w7.5-fold) and nitrite (w2.5-fold), indicating an
intact enterosalivary circuit in hypercholesterolemic patients.
Once absorbed, inorganic nitrate consumed from the diet is
extracted from the blood by the salivary glands (42) and con-
sequently secreted into the oral cavity (43). The commensal
bacteria reduce the nitrate to nitrite. This nitrite is swallowed
and appears within the circulation (21, 44). We have shown that
this circuit remained functional over the 6-wk once daily regi-
men with no evidence of tachphylaxis. Dietary nitrate caused a
7.7-fold increase in circulating nitrate concentrations after 3 h
with an identical rise after 6 wk. These changes were associated
with rises in plasma [nitrite] of 2.0- and 2.5-fold at 3 h and
6 wk, respectively; the increase in plasma nitrite concentrations
FIGURE 5 Dietary nitrate decreases platelet monocyte aggregate concentrations. Mean 6 SD effects of 6 wk of dietary nitrate consumption (250 mL
nitrate-rich juice/d) or placebo consumption (250 mL nitrate-depleted juice/d) on flow-cytometry measures of PMA (A) and the percentage of PMA formation
for groups before and after intake of nitrate-rich juice and placebo juice (B). (C) Change in % PMA formation over 6 wk in the 2 groups expressed as mean
(95% CI). Data shown are n = 25 for the nitrate group and n = 27 for the placebo group. **Significant for within-group comparisons of baseline compared with
postnitrate consumption, P , 0.01 (paired Student’s t test). *Significant for the comparison between groups, P , 0.05 (unpaired t test). PMA, platelet-
monocyte aggregate.
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FIGURE 6 Dietary nitrate results in changes in the oral microbiome. The use of a bacterial community profile analysis by means of the mothur pipeline
(16S ribosomal RNA gene) identified 78 different OTUs, the proportions of which were altered by dietary nitrate treatment. The statistical analysis was
conducted with the use of an AMOVA (38) for assessment of the change between groups in the oral microbial community (39). The AMOVA gave P , 0.001
for the within-group comparison between baseline and post-nitrate and P = 0.001 for the between-group comparison of post-placebo compared with post-
nitrate. Of these OTUs, those that had their numbers increase post-treatment and that made up .1% of the post-treatment community were Neisseria
flavescens and Rothia mucilaginosa. (A) Plot depicts a principal coordinate analysis that was based on the ThetaYC metric, which compared the structure of
the communities (PC1 = 34.6% of variance explained; PC2 = 56.2%). Colored circles represent the 2 groups of the study. Blue and green circles represent
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possibly suggesting a progressively increased nitrate reduction
with persistent dietary nitrate ingestion.
This apparent improvement in circulating nitrite concentra-
tions was associated with a shift in the bacterial community
within the oral cavity with raised numbers of N. flavescens and
R. mucilaginosa, which are species that exhibit denitrification
activity (45, 46). These findings intimate a shift in the oral
microbiome in favor of organisms that are capable of nitrate
reduction. In healthy volunteers, the nitrite:nitrate in the oral
cavity is 0.3 (47). In this study, the ratio of the change from
baseline of nitrite:nitrate in the saliva 3 h after nitrate adminis-
tration was 0.35 6 0.07, and at the 6-wk time point, it was 0.41 6
0.06; these values support the hypothesis of an increased nitrate
reduction at 6 wk. N. flavescens and R. mucilaginosa are nor-
mally regarded as obligate aerobes, whereas the biofilms that
form on oral surfaces rapidly become anaerobic with time, and
plaque bacterial communities are dominated by facultative and
obligate anaerobes. It is interesting that Neisseria, in particular,
can grow under anaerobic conditions with nitrate or nitrite
acting as an electron acceptor (45, 46). Neisseria was recently
reported to be one of the principal oral bacterial genera re-
sponsible for the nitrate reduction in healthy volunteers (48).
Additional prospective studies that assess whether persistent
dietary nitrate ingestion might provide improved nitrate bio-
activation in the longer term are warranted.
In this study, we showed that dietary nitrate ingestion resulted
in an increase in FMD (w24%) and, thus, an improvement of
vascular function. The beneficial effects of nitrate were evident
at 3 h after the first dose as well as at 6 wk, which indicated no
tachyphylaxis over time and suggested that the mechanisms
underlying these effects involve the acute modification of
pathways that result in immediate functional effects. Our find-
ings differ from recent observations in patients with diabetes
where no effect of daily dietary nitrate (2 wk of 7.5 mmol/d) was
evident (18) but are in accord with our own (albeit unpowered)
observations in hypertensive patients who consumed a single
dietary nitrate dose (w6 mmol) for 4 wk (17) where dietary
nitrate improved FMD responses. The reasons for the differ-
ences were unlikely to be related to the dose (although the study
by Benjamin et al. (18) in patients with diabetes used a dose that
was w1.5 mmol higher than that used in the current study) but
may have been related to the duration of treatment, a resistance
to inorganic nitrate in patients with diabetes, or insufficient
power.
Dietary nitrate treatment also resulted in modest improve-
ments in both the aPWVand augmentation index, both of which
are measures of arterial stiffness. Previous assessments in aged
mice showed that nitrite supplementation for 3 wk resulted in the
destiffening of the aorta because of a reduced concentration of
oxidative stress-induced advanced glycation end products (49).
Whether this mechanism might underlie the effects seen in this
study is uncertain but warrants assessment. It is possible that the
improvements in vascular function, particularly in the aPWV but
also the FMD, were secondary to decreases in BP. However, our
post hoc correlation analyses showed no association between the
change in vascular function and BP. Additional studies powered
to apply multivariate analyses to interrogate these issues more
closely are warranted.
We have previously speculated that the provision of nitrite as
a substrate to certain nitrite reductases, particularly the enzyme
xanthine oxidoreductase (XOR), not only results in NO gener-
ation but might also result in reductions of oxidative stress by
competing for electrons that are required for oxygen reduction
(50). Conventional XOR activity (i.e., the conversion of xanthine
to uric acid) occurs at the molybdenum-binding site of the en-
zyme, which is also the site of nitrite reduction (51, 52). Our
exploratory analyses herein showing apparent reduced concen-
trations of uric acid with nitrate treatment supports the suggestion
of an effect at the level of the XOR enzyme. High concentrations
of xanthine prevent nitrite reduction by XOR (53); however,
whether nitrite might compete with xanthine at the molybdenum
site of the enzyme is unknown and worth investigating.
We showed no evidence of alterations in lipid concentrations in
contrast with preclinical studies in hypercholesterolemic C57BL/
6J mice (54) and a small study in hypercholesterolemic patients
(55). The reasons for this difference are uncertain, but our study
was not powered to detect small reductions in LDL or tri-
glyceride, and larger studies to assess this difference may be
worthwhile.
Dietary nitrate treatment was associated with small but sig-
nificant reductions in markers of platelet activation. Such an
effect may be beneficial because activated platelets are thought to
play a role in the progression of atherosclerotic disease in humans
(56, 57). PMA assessment has been proposed to be a superior
marker of platelet activation compared with surface P-selectin,
and preclinical studies in mice have suggested that targeting
PMAmay yield therapeutic benefit because these aggregates play
a crucial role in inducing endothelial dysfunction and consequent
atheroma formation (58). Although the concentrations of P-selectin
in unstimulated platelets were not significantly altered by dietary
nitrate treatment, a small but significant reduction in P-selectin
expression in response to ex vivo treatment with platelet acti-
vating stimuli suggest that reduction of stimulated P-selectin
expression may underlie the reduced numbers of PMA (these
aggregates form because of an interaction between platelet
P-selectin and monocyte P-selectin glycoprotein ligand-1). NO
lowers platelet reactivity through reductions in P-selectin ex-
pression (59); this effect has been implicated in nitrate- and
nitrite-induced repression of platelet reactivity in humans (16,
60). A prospective study designed to test this directly is war-
ranted.
The exact molecular mechanisms that underlie the improve-
ments in vascular function are uncertain. However, it is thought
that the reduced bioavailability of NO in hypercholesterolemia
relates to an increased oxidative stress (61, 62). This relation, in
turn, is thought to result in the scavenging of NO that triggers
systemic inflammation. Because the FMD response is thought to
be due in part to endothelium-derived NO release (63, 64), the
baseline and after 6 wk of placebo intake, respectively, and purple and red circles represent baseline and after 6 wk of once-daily intake (5 mmol) of dietary
nitrate juice, respectively. (B) Representation of the relative abundances of R. mucilaginosa and N. flavescens at baseline and postnitrate or postplacebo
treatment of 6 wk. Data are shown for baseline and 6-wk values for n = 16 in the nitrate group and n = 14 in the placebo group. Solid lines denote group means,
and dotted lines denote group medians. AMOVA, analysis of molecular variance; OTU, operational taxonomic unit.
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increase in response might reflect an improvement in NO activity
that is due to reductions in inflammation-induced oxidative stress
and NO scavenging. Our analyses indicated that, although hs-
CRP was not different in the whole cohort, in individuals with
high baseline concentrations, a trend for a reduction was evident.
We also observed a trend for a reduction of neutrophil chemokine
CXCL1, which is a chemokine that has been implicated in human
atherosclerotic disease (65), although concentrations of oxidized
LDL, as a marker of oxidative stress, were not different between
the groups. Additional prospective and appropriately powered
studies that are designed to test whether dietary nitrate reduces
inflammation and oxidative stress in hypercholesterolemia are
required.
The safety profiles of dietary nitrate and nitrite have been much
debated particularly with respect to methemoglobin concentra-
tions and associations of dietary nitrite consumption and en-
dogenous N-nitrosamine formation with gastric cancer (66). In
this study, there was no evidence of methemoglobinemia and
a small increase in apparent total NOC after nitrate. However,
the concentrations of the latter fell within the range observed in
healthy individuals and were lower than those thought to be
associated with high risk of intestinal cancer. A major limitation
of the NOC measurements was that we could not exclude the
possibility that the iron-nitrosyl species in the urine were formed
after sample collection. The pH of urine is generally slightly
acidic and will favor NO release from nitrite and, thus, the
potential for nitrosation of any free haem groups within the
urine. Additional studies are warranted to clarify these issues.
We did not measure the effect of dietary nitrate on direct NO-
stimulated increases in blood flow, which have conventionally
been assessed with the use of glyceryltrinitrate. Therefore, we
could not exclude the possibility that changes in the reactivity of
the underlying smooth muscle might also have contributed to the
improved vascular function. In addition, a number of mechanistic
and exploratory analyses were conducted for which the study was
not powered, including all of the inflammatory mediator, ap-
parent NOC, and microbiome analyses. Additional prospective
studies that are powered for each of these outcome measures are
required to confirm the hypotheses proposed.
In conclusion, this study supports the use of dietary nitrate
as a safe, well-tolerated, and potentially powerful prevention
strategy in CVD in individuals with early vascular dysfunction.
This strategy is evidenced by improvements in FMD, vascular
stiffness, and the platelet inflammatory profile. Long-term out-
come studies are required to test the merits of a dietary nitrate
strategy.
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